Annual accounts receivable:
$6.21B+$544.60M(+9.61%)Summary
- As of today (May 27, 2025), REGN annual accounts receivable is $6.21 billion, with the most recent change of +$544.60 million (+9.61%) on December 31, 2024.
- During the last 3 years, REGN annual accounts receivable has risen by +$175.40 million (+2.91%).
- REGN annual accounts receivable is now at all-time high.
Performance
REGN Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$5.56B-$650.90M(-10.48%)Summary
- As of today (May 27, 2025), REGN quarterly accounts receivable is $5.56 billion, with the most recent change of -$650.90 million (-10.48%) on March 31, 2025.
- Over the past year, REGN quarterly accounts receivable has increased by +$338.80 million (+6.49%).
- REGN quarterly accounts receivable is now -20.54% below its all-time high of $7.00 billion, reached on June 30, 2021.
Performance
REGN Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
REGN Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +9.6% | +6.5% |
| 3 y3 years | +2.9% | +14.9% |
| 5 y5 years | +163.2% | +119.7% |
REGN Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +16.6% | -10.5% | +14.9% |
| 5 y | 5-year | at high | +163.2% | -20.5% | +133.6% |
| alltime | all time | at high | >+9999.0% | -20.5% | >+9999.0% |
REGN Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $5.56B(-10.5%) |
| Dec 2024 | $6.21B(+9.6%) | $6.21B(+1.7%) |
| Sep 2024 | - | $6.11B(+6.8%) |
| Jun 2024 | - | $5.72B(+9.5%) |
| Mar 2024 | - | $5.22B(-7.9%) |
| Dec 2023 | $5.67B(+6.4%) | $5.67B(+1.5%) |
| Sep 2023 | - | $5.58B(+9.0%) |
| Jun 2023 | - | $5.12B(+0.1%) |
| Mar 2023 | - | $5.12B(-3.9%) |
| Dec 2022 | $5.33B(-11.7%) | $5.33B(-4.0%) |
| Sep 2022 | - | $5.55B(+7.5%) |
| Jun 2022 | - | $5.16B(+6.7%) |
| Mar 2022 | - | $4.84B(-19.8%) |
| Dec 2021 | $6.04B(+46.7%) | $6.04B(+10.7%) |
| Sep 2021 | - | $5.45B(-22.1%) |
| Jun 2021 | - | $7.00B(+67.7%) |
| Mar 2021 | - | $4.17B(+1.4%) |
| Dec 2020 | $4.11B(+74.3%) | $4.11B(+15.8%) |
| Sep 2020 | - | $3.55B(+49.3%) |
| Jun 2020 | - | $2.38B(-6.0%) |
| Mar 2020 | - | $2.53B(+7.2%) |
| Dec 2019 | $2.36B(+5.2%) | $2.36B(-11.3%) |
| Sep 2019 | - | $2.66B(+8.3%) |
| Jun 2019 | - | $2.46B(+6.5%) |
| Mar 2019 | - | $2.31B(+2.8%) |
| Dec 2018 | $2.24B(+13.6%) | $2.24B(+1.8%) |
| Sep 2018 | - | $2.20B(+8.0%) |
| Jun 2018 | - | $2.04B(+4.9%) |
| Mar 2018 | - | $1.94B(-1.5%) |
| Dec 2017 | $1.97B(+22.5%) | $1.97B(+0.1%) |
| Sep 2017 | - | $1.97B(+6.9%) |
| Jun 2017 | - | $1.84B(+5.4%) |
| Mar 2017 | - | $1.75B(+8.6%) |
| Dec 2016 | $1.61B(+9.8%) | $1.61B(-2.0%) |
| Sep 2016 | - | $1.64B(-6.2%) |
| Jun 2016 | - | $1.75B(-6.1%) |
| Mar 2016 | - | $1.87B(+27.1%) |
| Dec 2015 | $1.47B(+50.3%) | $1.47B(+2.0%) |
| Sep 2015 | - | $1.44B(+3.2%) |
| Jun 2015 | - | $1.40B(+4.2%) |
| Mar 2015 | - | $1.34B(+37.1%) |
| Dec 2014 | $976.37M(+2.2%) | $976.37M(+5.3%) |
| Sep 2014 | - | $927.25M(+3.7%) |
| Jun 2014 | - | $893.92M(-14.7%) |
| Mar 2014 | - | $1.05B(+9.7%) |
| Dec 2013 | $954.97M(+37.8%) | $954.97M(-3.8%) |
| Sep 2013 | - | $992.82M(+13.3%) |
| Jun 2013 | - | $876.02M(+9.1%) |
| Mar 2013 | - | $802.64M(+15.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $693.12M(+572.7%) | $693.12M(+36.8%) |
| Sep 2012 | - | $506.68M(+44.9%) |
| Jun 2012 | - | $349.64M(+119.3%) |
| Mar 2012 | - | $159.46M(+54.8%) |
| Dec 2011 | $103.03M(+25.8%) | $103.03M(+31.3%) |
| Sep 2011 | - | $78.45M(-7.2%) |
| Jun 2011 | - | $84.56M(-4.1%) |
| Mar 2011 | - | $88.16M(+7.6%) |
| Dec 2010 | $81.92M(+24.9%) | $81.92M(-0.4%) |
| Sep 2010 | - | $82.29M(-13.6%) |
| Jun 2010 | - | $95.20M(+32.5%) |
| Mar 2010 | - | $71.86M(+9.6%) |
| Dec 2009 | $65.57M(+86.2%) | $65.57M(-3.2%) |
| Sep 2009 | - | $67.77M(+12.9%) |
| Jun 2009 | - | $60.05M(+24.6%) |
| Mar 2009 | - | $48.21M(+36.9%) |
| Dec 2008 | $35.21M(+92.2%) | $35.21M(-16.6%) |
| Sep 2008 | - | $42.21M(+28.5%) |
| Jun 2008 | - | $32.84M(-0.4%) |
| Mar 2008 | - | $32.96M(+79.9%) |
| Dec 2007 | $18.32M(+144.5%) | $18.32M(+67.0%) |
| Sep 2007 | - | $10.97M(-46.4%) |
| Jun 2007 | - | $20.48M(-39.1%) |
| Mar 2007 | - | $33.63M(+348.8%) |
| Dec 2006 | $7.49M(-79.5%) | $7.49M(-5.6%) |
| Sep 2006 | - | $7.94M(-34.6%) |
| Jun 2006 | - | $12.14M(+10.3%) |
| Mar 2006 | - | $11.01M(-69.9%) |
| Dec 2005 | $36.52M(-15.3%) | $36.52M(+246.6%) |
| Sep 2005 | - | $10.54M(-37.4%) |
| Jun 2005 | - | $16.83M(+62.3%) |
| Mar 2005 | - | $10.37M(-75.9%) |
| Dec 2004 | $43.10M(+177.6%) | $43.10M(+73.3%) |
| Sep 2004 | - | $24.87M(-2.1%) |
| Jun 2004 | - | $25.40M(-57.6%) |
| Mar 2004 | - | $59.88M(+285.6%) |
| Dec 2003 | $15.53M(+286.6%) | $15.53M(+68.8%) |
| Sep 2003 | - | $9.20M(+16.8%) |
| Jun 2003 | - | $7.87M(+8.7%) |
| Mar 2003 | - | $7.24M(+80.2%) |
| Dec 2002 | $4.02M(+35.0%) | $4.02M(-11.1%) |
| Sep 2002 | - | $4.52M(+51.4%) |
| Jun 2002 | - | $2.99M(+9.0%) |
| Mar 2002 | - | $2.74M(-7.9%) |
| Dec 2001 | $2.98M(-78.5%) | $2.98M(-16.1%) |
| Sep 2001 | - | $3.55M(-19.0%) |
| Jun 2001 | - | $4.38M(-49.1%) |
| Mar 2001 | - | $8.61M(-37.8%) |
| Dec 2000 | $13.84M | $13.84M |
FAQ
- What is Regeneron Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual accounts receivable year-on-year change?
- What is Regeneron Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly accounts receivable year-on-year change?
What is Regeneron Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of REGN is $6.21B
What is the all time high annual accounts receivable for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual accounts receivable is $6.21B
What is Regeneron Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, REGN annual accounts receivable has changed by +$544.60M (+9.61%)
What is Regeneron Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of REGN is $5.56B
What is the all time high quarterly accounts receivable for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly accounts receivable is $7.00B
What is Regeneron Pharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, REGN quarterly accounts receivable has changed by +$338.80M (+6.49%)